5.95
-0.05
(-0.83%)
At close: 8:19:31 AM GMT+2
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 3 | 5 |
| Avg. Estimate | 38.9M | 28.8M | 133.93M | 196.84M |
| Low Estimate | 38.7M | 28M | 128M | 149.4M |
| High Estimate | 39M | 30M | 145.1M | 249M |
| Year Ago Sales | -- | 806.12k | 43.47M | 133.93M |
| Sales Growth (year/est) | 0.00% | 3,472.67% | 208.09% | 46.97% |
EPS Trend
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0 | 0 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| 19KA.F | -- | -- | -- | -- |
| S&P 500 | 6.74% | 5.74% | 9.21% | 14.18% |
Upgrades & Downgrades
| Reiterates | Needham: Buy to Buy | 4/9/2025 |
| Maintains | D. Boral Capital: Buy to Buy | 4/8/2025 |
| Reiterates | RBC Capital: Outperform to Outperform | 3/26/2025 |
| Maintains | Needham: Buy to Buy | 3/26/2025 |
| Maintains | D. Boral Capital: Buy to Buy | 3/25/2025 |
| Initiated | Leerink Partners: Outperform | 3/7/2025 |
Related Tickers
ARDX.MX Ardelyx, Inc.
105.50
0.00%
B9A.F BioArctic AB (publ)
14.93
+1.50%
RPD.MU Royalty Pharma plc
28.20
0.00%
2HA.F Spero Therapeutics, Inc.
0.5290
+6.55%
05Y.MU Vivoryon Therapeutics NV
1.8260
-0.87%
PROT Proteonomix, Inc.
0.0000
-90.00%
BT3.BE Lineage Cell Therapeutics Inc
0.4020
+12.29%
HQ1.MU Oruka Therapeutics Inc. R
6.65
+3.91%
7PO.F Poxel S.A.
0.5090
-3.96%
P0F.F Egetis Therapeutics AB (publ)
0.3100
-5.20%